DEA and FDA Issue Joint Letter to the Public on Actions to Address Shortages in Prescription Stimulants

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Announcements

DEA and FDA Issue Joint Letter to the Public on Actions to Address Shortages in Prescription Stimulants

August 01, 2023

Announcement

Download Document

On August 1, 2023, the Drug Enforcement Administration (DEA) and U.S. Food and Drug Administration (FDA) issued a joint letter updating the public on the ongoing prescription stimulant shortages impacting patients across the United States and actions to resolve these shortages. The DEA and FDA are committed to working together on this issue and providing up-to-date information to the public. We will continue to do all we can to prevent stimulant drug shortages, limit their impact, and resolve them as quickly as possible.

Attachments

DEA and FDA Issue Joint Letter to the Public